bmy88 register
Through all the upsets, unexpected rises and falls, there are nine teams still in the mix to play in the conference championship game. No. 14 Arizona State and No. 17 Iowa State have the best odds, yet a multitude of scenarios could play out — 256 to be exact. There's even the possibility of an eight-team tie. It may take a mathematician to figure out which teams are in the Dec. 7 game in Arlington, Texas — even for the ones who win. Star power Travis Hunter, Colorado. The Buffaloes' two-way star has excelled on both sides of the field, making him one of the favorites to win the Heisman Trophy. Cam Skattebo, Arizona State. The senior running back can do a little of everything, but excels at punishing would-be tacklers. He's one of the nation's leaders in yards after contact and the focal point of the Sun Devils' offense. Shadeur Sanders, Colorado. If it weren't for Hunter, Sanders might be the Heisman favorite. The son of coach Deion Sanders, Shedeur is fifth nationally with 3,488 yards passing and has been a big part of the Buffaloes' turnaround. DJ Giddens, Kansas State. The Wildcats' running back is one of the nation's most versatile players. He is ninth nationally with 1,271 rushing yards and has added 21 receptions for 258 yards. Tetairoa McMillan, Arizona. The Wildcats have struggled this season, but McMillan has not. He is third nationally with 1,251 receiving yards with seven touchdowns on 78 catches. Jacob Rodriguez, Texas Tech. The Red Raiders' junior linebacker leads the Big 12 with 68 tackles, averaging 10.2 per game. He also has four sacks. Brendan Mott, Kansas State. He's a menace to opposing quarterbacks, leading the Big 12 with 8 1/2 sacks. Going bowling The Big 12 has nine teams already bowl eligible and two more a win away. The winner of the Big 12 championship game will be in the mix for a College Football Playoff spot. Arizona State, Iowa State, No. 19 BYU, Colorado, Kansas State, Baylor, TCU, Texas Tech and West Virginia have already clinched bowl berths. Kansas and Cincinnati can get into the postseason with wins this weekend. Hot seats Gus Malzahn, UCF. Despite successes in recruiting, the Knights are 10-14 in two seasons since moving to the Big 12. Maybe not enough to get shown the door this year, but another mediocre season could lead UCF to make a change. Kyle Whittingham, Utah. Whittingham was one of the Pac-12's best coaches, leading the Utes to consecutive conference titles. Utah was expected to contend for the Big 12 title its first year in the league, but enters the final weekend 1-7 in conference play, which could push Whittingham toward retirement since it's doubtful he'd be fired. Neal Brown, West Virginia. The Mountaineers' coach was in a precarious spot at the end of last season and West Virginia hasn't lived up to expectations this season. The Mountaineers are eligible to go to a bowl game for the second straight season, but Brown could be on the hot seat even after signing a contract extension before the season. Youth movement Josiah Trotter, West Virginia. The redshirt freshman is the latest Trotter to have success at the linebacker position, following the footsteps of his father, former Philadelphia Eagles player Jeremiah Trotter, and brother Jeremiah Trotter Jr., a current Eagles linebacker. Sam Leavitt, Arizona State. The Michigan State transfer has been just what the Sun Devils' needed: an agile quarterback who extends plays with his legs and rarely makes bad decisions. Bryson Washington, Baylor. The Bears' running back has rushed for 812 yards — 196 against TCU — and 10 TDs. Recruiting watch TCU has the Big 12's highest rated 2025 recruiting class with six four-star players among 26 commitments, according to the 247 Sports composite. Receiver Terry Shelton of Carrollton, Texas, is the highest-rated recruit at 71st nationally. Baylor is next with five five-star players among its 20 commitments, including running back Michael Turner, rated 13th at his position out of North Richland Hills, Texas. Texas Tech is ranked seventh in the Big 12, but has four four-star recruits.‘Should I just buy a new Mazda instead?’: Woman drives this Lexus home. Then she gets cold feet about paying $50,000
Phase 3 Study Results Demonstrated Three Year, Disease-Free Survival of 96% THOUSAND OAKS, Calif. , Dec. 7, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data demonstrating that adding BLINCYTO ® (blinatumomab) to chemotherapy significantly improves disease-free survival (DFS) in newly diagnosed pediatric patients with National Cancer Institute (NCI) standard risk (SR) B-cell acute lymphoblastic leukemia (B-ALL) of average or higher risk of relapse. The data are from a Phase 3 study (AALL1731) conducted by the Children's Oncology Group. The results were simultaneously published in the New England Journal of Medicine and will be presented during the plenary session on Sunday, Dec. 8 , at 2 p.m. PT at the 66 th American Society of Hematology (ASH) Annual Meeting & Exposition in San Diego . "Over the last decade, BLINCYTO has reshaped the treatment landscape for B-ALL, offering a critical lifeline for thousands of adult and pediatric patients," said Jay Bradner , M.D., executive vice president of Research and Development and chief scientific officer at Amgen. "These powerful new data leave us little doubt about the profound impact of this medicine for a large number of children affected by this disease. We are grateful to the Children's Oncology Group, along with the patients, families and clinical teams, for their dedication and partnership in advancing this critical study to improve the lives of children with cancer." Based on the results of the first pre-specified interim analysis for efficacy, the study met its primary endpoint of DFS and study randomization was terminated early based on the recommendation from the data and safety monitoring committee due to the benefit observed in the BLINCYTO arm compared to the chemotherapy-only arm. Overall, the 3-year DFS was 96.0% for patients treated with chemotherapy plus BLINCYTO compared to 87.9% for those treated with only chemotherapy. The hazard ratio (HR) was 0.39 [95% confidence interval (CI) 0.24-0.64], indicating a 61% reduction in the risk of disease relapse, secondary malignant neoplasm or remission death with BLINCYTO. At 3 years, more patients remained alive and cancer free when treated with BLINCYTO plus chemotherapy compared to chemotherapy alone. "The AALL1731 study results are truly practice-changing, further solidifying blinatumomab's role as the standard of care for a large number of children with B-ALL," said Sumit Gupta , M.D., Ph.D., FRCPC, co-chair of the Children's Oncology Group AALL1731 study and oncologist and clinician investigator, Division of Haematology/Oncology at The Hospital for Sick Children (SickKids) and associate professor of pediatrics at the University of Toronto . "These breakthrough data showing a significant improvement in disease-free survival are poised to bring substantial clinical value to children with newly diagnosed B-ALL." The addition of BLINCYTO to chemotherapy in standard risk patients resulted in outcomes similar to those previously achieved in only the most favorable pediatric risk subsets. Among SR-Average patients, 3-year DFS was 97.5% for patients treated with BLINCYTO compared to 90.2% for those treated with only chemotherapy (HR 0.33, CI 0.15-0.69). For SR-High patients, 3-year DFS was 94.1% for those treated with BLINCYTO compared to 84.8% for those treated with only chemotherapy (HR 0.45, 95% CI 0.24-0.85). "Relapsed ALL remains a major cause of pediatric cancer mortality, with nearly half of the relapses occurring in children with standard-risk B-ALL," said Rachel E. Rau , M.D., co-chair of the Children's Oncology Group AALL1731 study, pediatric hematologist-oncologist at Seattle Children's Hospital and associate professor of pediatrics at the University of Washington . "These findings underscore the progress made with blinatumomab in preventing relapse and support its role as a critical addition to current therapeutic strategies." Safety results are consistent with the known safety profile of BLINCYTO. BLINCYTO has demonstrated a positive balance of benefits and risks, with only 0.3% of first courses associated with Grade 3+ cytokine release syndrome (CRS) and 0.7% with seizures. A higher risk of infections was observed in the BLINCYTO arm. These results provide the first evidence supporting BLINCYTO for use in the consolidation phase in newly diagnosed pediatric Philadelphia chromosome-negative (Ph-) B-ALL patients. This groundbreaking first-in-class Bispecific T-cell Engager (BiTE ® ) therapy is now backed by additional evidence reinforcing its role in redefining a standard of care for both adult and pediatric patients, starting from one month old, regardless of measurable residual disease (MRD) status. The findings further establish BLINCYTO as a versatile first-line consolidation therapy across all ages and treatment backbones. The NCI's Cancer Therapy Evaluation Program (CTEP), which sponsored the study will share data with the U.S. Food and Drug Administration as part of their ongoing communications relating to the trial. About The Children's Oncology Group The Children's Oncology Group (childrensoncologygroup.org), a member of the NCI National Clinical Trials Network (NCTN), is the world's largest organization devoted exclusively to childhood and adolescent cancer research. The Children's Oncology Group unites over 10,000 experts in childhood cancer at more than 200 leading children's hospitals, universities and cancer centers across North America , Australia , New Zealand and Saudi Arabia in the fight against childhood cancer. Today, more than 80% of the 15,000 children and adolescents diagnosed with cancer each year in the United States are cared for at Children's Oncology Group member institutions. Research performed by Children's Oncology Group institutions over the past 50 years has transformed childhood cancer from a virtually incurable disease to one with a combined 5-year survival rate of 86%. The Children's Oncology Group's mission is to improve the cure rate and outcomes for all children with cancer. About AALL1731 (NCT03914625) The AALL1731 study was a Phase 3 randomized trial to determine if two non-sequential cycles of BLINCYTO added to chemotherapy improved disease-free survival (DFS) in children with newly diagnosed pediatric National Cancer Institute (NCI) standard risk (SR) B-cell acute lymphoblastic leukemia (B-ALL). The study enrolled 4,264 newly diagnosed NCI SR B-ALL patients, of whom 2,334 were risk stratified at the end of induction therapy as either SR-Average or SR-High. At the first planned interim efficacy analysis (data cutoff June 30, 2024 ), 1,440 of the eligible and evaluable patients had been randomized. The AALL1731 study was designed and conducted independently from industry. The Cancer Therapy Evaluation Program (CTEP) of the NCI sponsored the trial and provided funding to the Children's Oncology Group to conduct the study. NCI is part of the National Institutes of Health (NIH). In addition, Amgen provided BLINCYTO and support through an NCI Cooperative Research and Development Agreement. About Acute Lymphoblastic Leukemia (ALL) ALL, also known as acute lymphoblastic leukemia, is a fast-growing type of blood cancer that develops in the bone marrow and can sometimes spread to other parts of the body, including the lymph nodes, liver, spleen and central nervous system. ALL is a rare disease, with an estimated 6,550 new cases, affecting both children and adults, diagnosed in the U.S. in 2024. 1 B-ALL begins in immature cells that would normally develop into B-cell lymphocytes, which are white blood cells that grow in bone marrow. 2,3 B-ALL is the most common type of ALL, constituting approximately 75% of cases in adults and approximately 88% in children, the most common cancer in children. 4,5 About BLINCYTO ® (blinatumomab) BLINCYTO is the first globally approved Bispecific T-cell Engager (BiTE ® ) immuno-oncology therapy that targets CD19 surface antigens on B cells. BiTE ® molecules fight cancer by helping the body's immune system detect and target malignant cells by engaging T cells (a type of white blood cell capable of killing other cells perceived as threats) to cancer cells. By bringing T cells near cancer cells, the T cells can inject toxins and trigger cancer cell death (apoptosis). BiTE ® immuno-oncology therapies are currently being investigated for their potential to treat a wide variety of cancers. BLINCYTO was granted Breakthrough Therapy and Priority Review designations by the U.S. FDA and is approved in the U.S. for the treatment of: In the European Union (EU), BLINCYTO is indicated as monotherapy for the treatment of: BLINCYTO ® IMPORTANT SAFETY INFORMATION WARNING: CYTOKINE RELEASE SYNDROME and NEUROLOGICAL TOXICITIES including IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME Contraindications BLINCYTO ® is contraindicated in patients with a known hypersensitivity to blinatumomab or to any component of the product formulation. Warnings and Precautions Adverse Reactions Dosage and Administration Guidelines INDICATIONS BLINCYTO ® (blinatumomab) is indicated for the treatment of CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult and pediatric patients one month and older with: Please see BLINCYTO ® full Prescribing Information , including BOXED WARNINGS. About Bispecific T-Cell Engager (BiTE ® ) Technology BiTE technology is a targeted immuno-oncology platform that is designed to engage a patient's own T cells to any tumor-specific antigen, activating the cytotoxic potential of T cells to eliminate detectable cancer. The BiTE immuno-oncology platform has the potential to treat different cancer types through tumor-specific antigens. The BiTE platform has a goal of leading to off-the-shelf solutions, which have the potential to make innovative T-cell treatment available to all providers when their patients need it. For more than a decade, Amgen has been advancing this innovative technology, which has demonstrated strong efficacy in hematological malignancies and now a solid tumor with the approval of IMDELLTRA. Amgen remains committed to progressing multiple BiTE molecules across a broad range of hematologic and solid tumor malignancies, paving the way for additional applications in more tumor types. Amgen is further investigating BiTE technology with the goal of enhancing patient experience and therapeutic potential. To learn more about BiTE technology, visit BiTE ® Technology 101 . About Amgen Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions . Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average ® , and it is also part of the Nasdaq-100 Index ® , which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization. For more information, visit Amgen.com and follow Amgen on X , LinkedIn , Instagram , TikTok , YouTube and Threads . Amgen Forward-Looking Statements This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla ® (apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), Amgen's acquisitions of Teneobio, Inc., ChemoCentryx, Inc., or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon's business, performance and opportunities, any potential strategic benefits, synergies or opportunities expected as a result of such acquisition, and any projected impacts from the Horizon acquisition on Amgen's acquisition-related expenses going forward), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on Amgen's business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including its most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise. No forward-looking statement can be guaranteed and actual results may differ materially from those Amgen projects. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for Amgen to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and Amgen expects similar variability in the future. Even when clinical trials are successful, regulatory authorities may question the sufficiency for approval of the trial endpoints Amgen has selected. Amgen develops product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as Amgen may have believed at the time of entering into such relationship. Also, Amgen or others could identify safety, side effects or manufacturing problems with its products, including its devices, after they are on the market. Amgen's results may be affected by its ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing its products and global economic conditions. In addition, sales of Amgen's products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, Amgen's research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Amgen's business may be impacted by government investigations, litigation and product liability claims. In addition, Amgen's business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If Amgen fails to meet the compliance obligations in the corporate integrity agreement between Amgen and the U.S. government, Amgen could become subject to significant sanctions. Further, while Amgen routinely obtains patents for its products and technology, the protection offered by its patents and patent applications may be challenged, invalidated or circumvented by its competitors, or Amgen may fail to prevail in present and future intellectual property litigation. Amgen performs a substantial amount of its commercial manufacturing activities at a few key facilities, including in Puerto Rico, and also depends on third parties for a portion of its manufacturing activities, and limits on supply may constrain sales of certain of its current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for Amgen's manufacturing activities, the distribution of Amgen's products, the commercialization of Amgen's product candidates, and Amgen's clinical trial operations, and any such events may have a material adverse effect on Amgen's product development, product sales, business and results of operations. Amgen relies on collaborations with third parties for the development of some of its product candidates and for the commercialization and sales of some of its commercial products. In addition, Amgen competes with other companies with respect to many of its marketed products as well as for the discovery and development of new products. Further, some raw materials, medical devices and component parts for Amgen's products are supplied by sole third-party suppliers. Certain of Amgen's distributors, customers and payers have substantial purchasing leverage in their dealings with Amgen. The discovery of significant problems with a product similar to one of Amgen's products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on its business and results of operations. Amgen's efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology Amgen has acquired, may not be successful. There can be no guarantee that Amgen will be able to realize any of the strategic benefits, synergies or opportunities arising from the Horizon acquisition, and such benefits, synergies or opportunities may take longer to realize than expected. Amgen may not be able to successfully integrate Horizon, and such integration may take longer, be more difficult or cost more than expected. A breakdown, cyberattack or information security breach of Amgen's information technology systems could compromise the confidentiality, integrity and availability of Amgen's systems and Amgen's data. Amgen's stock price may be volatile and may be affected by a number of events. Amgen's business and operations may be negatively affected by the failure, or perceived failure, of achieving its environmental, social and governance objectives. The effects of global climate change and related natural disasters could negatively affect Amgen's business and operations. Global economic conditions may magnify certain risks that affect Amgen's business. Amgen's business performance could affect or limit the ability of the Amgen Board of Directors to declare a dividend or its ability to pay a dividend or repurchase its common stock. Amgen may not be able to access the capital and credit markets on terms that are favorable to it, or at all. Any scientific information discussed in this news release relating to new indications for Amgen's products is preliminary and investigative and is not part of the labeling approved by the U.S. Food and Drug Administration for the products. The products are not approved for the investigational use(s) discussed in this news release, and no conclusions can or should be drawn regarding the safety or effectiveness of the products for these uses. CONTACT: Amgen, Thousand Oaks Elissa Snook , 609-251-1407 (media) Justin Claeys , 805-313-9775 (investors) References View original content to download multimedia: https://www.prnewswire.com/news-releases/blincyto-blinatumomab-added-to-chemotherapy-significantly-improves-survival-in-newly-diagnosed-pediatric-patients-with-b-cell-precursor-acute-lymphoblastic-leukemia-b-all-302325381.html SOURCE AmgenYou Might Be Able to Install a Heat Pump Yourself. You Probably Shouldn't
SEOUL, South Korea (AP) — South Korea's embattled President Yoon Suk Yeol avoided an opposition-led attempt to impeach him over his short-lived imposition of martial law , as most ruling party lawmakers boycotted a parliamentary vote Saturday to deny a two-thirds majority needed to suspend his presidential powers. The scrapping of the motion is expected to intensify protests calling for Yoon’s ouster and deepen political chaos in South Korea, with a survey suggesting a majority of South Koreans support the president’s impeachment. Yoon’s martial law declaration drew criticism from his own ruling conservative People Power Party, but the party is also determined to oppose Yoon’s impeachment apparently because it fears losing the presidency to liberals. After the motion fell through, members of the main liberal opposition Democratic Party rallied inside the National Assembly, chanting slogans calling for Yoon's impeachment or resignation. The party's floor leader, Park Chan-dae, said it will soon prepare for a new impeachment motion. Opposition parties could submit a new impeachment motion after a new parliamentary session opens next Wednesday. “We'll surely impeach Yoon Suk Yeol, who is the greatest risk to Republic of Korea,” party leader Lee Jae-myung said. “We'll surely bring back this country to normal before Christmas Day or year's end.” Many experts worry Yoon won’t be able to serve out his remaining 2 1⁄2 years in office. They say some PPP lawmakers could eventually join opposition parties’ efforts to impeach Yoon if public demands for it grow further. The ruling party risks "further public outrage and national confusion if they don’t find a formula fast for Yoon’s departure,” said Duyeon Kim, a senior analyst at the Center for a New American Security in Washington. PPP chair Han Dong-hun said his party will seek Yoon’s “orderly” early exit but didn’t say when he can resign. Protests against Yoon are swelling On Saturday, tens of thousands of people packed several blocks of roads leading to the National Assembly, waving banners, shouting slogans and dancing. Protesters also gathered in front of PPP’s headquarters near the Assembly, shouting for its lawmakers to vote to impeach Yoon. A smaller crowd of Yoon’s supporters, which still seemed to be in the thousands, rallied elsewhere in Seoul, calling the impeachment attempt unconstitutional. Impeaching Yoon required support from 200 of the National Assembly's 300 members. The Democratic Party and five other small opposition parties, which filed the motion, have 192 seats combined. But only three lawmakers from PPP participated in the vote. The motion was scrapped without ballot counting because the number of votes didn’t reach 200. National Assembly Speaker Woo Won Shik called the result “very regrettable” and an embarrassing moment for the country’s democracy. If Yoon is impeached, his powers will be suspended until the Constitutional Court decides whether to remove him from office. If he is removed, an election to replace him must take place within 60 days. The president apologizes for turmoil Earlier Saturday, Yoon issued an apology over the martial law decree, saying he won’t shirk legal or political responsibility for the declaration and promising not to make another attempt to impose it. He said would leave it to his party to chart a course through the country’s political turmoil, “including matters related to my term in office.” “The declaration of this martial law was made out of my desperation. But in the course of its implementation, it caused anxiety and inconveniences to the public. I feel very sorry over that and truly apologize to the people who must have been shocked a lot,” Yoon said. Since taking office in 2022, Yoon has struggled to push his agenda through an opposition-controlled parliament and grappled with low approval ratings amid scandals involving himself and his wife. In his martial law announcement on Tuesday night, Yoon called parliament a “den of criminals” bogging down state affairs and vowed to eliminate “shameless North Korea followers and anti-state forces.” The declaration of martial law was the first of its kind in more than 40 years in South Korea. The turmoil has paralyzed South Korean politics and sparked alarm among key diplomatic partners like the U.S. and Japan. “Yoon’s credibility overseas has been undermined by declaring martial law, so he won’t be able to exercise leadership in his foreign policies especially when his days are numbered,” Kim, the analyst, said. “Its government bureaucracy will need to continue business as usual for existing alliance and foreign policy initiatives as best it can because there is a lot of important work to do globally.” Tuesday night saw special forces troops encircling the parliament building and army helicopters hovering over it, but the military withdrew after the National Assembly unanimously voted to overturn the decree, forcing Yoon to lift it before daybreak Wednesday. Eighteen lawmakers from the ruling party voted to reject Yoon’s martial law decree along with opposition lawmakers. PPP later decided to oppose Yoon's impeachment motion. Yoon’s speech fueled speculation that he and his party may push for a constitutional amendment to shorten his term, instead of accepting impeachment, as a way to ease public anger over the marital law and facilitate Yoon’s early exit from office. Lee told reporters that Yoon’s speech was “greatly disappointing” and that the only way forward is his immediate resignation or impeachment. His party called Yoon’s martial law “unconstitutional, illegal rebellion or coup.” Lawmakers on Saturday first voted on a bill appointing a special prosecutor to investigate stock price manipulation allegations surrounding Yoon’s wife. Yoon accused of ordering arrests of politicians On Friday, Han, who criticized Yoon’s martial law declaration, said he had received intelligence that during the brief period of martial law Yoon ordered the country’s defense counterintelligence commander to arrest unspecified key politicians based on accusations of “anti-state activities.” Hong Jang-won, first deputy director of South Korea’s spy agency, told lawmakers Friday that Yoon had ordered him to help the defense counterintelligence unit to detain key politicians including Han, Lee and Woo. The Defense Ministry said Friday it suspended three military commanders including the head of the defense counterintelligence unit over their involvement in enforcing martial law. Vice Defense Minister Kim Seon Ho has told parliament that Defense Minister Kim Yong Hyun ordered the deployment of troops to the National Assembly. Opposition parties accused Kim of recommending to Yoon to enforce martial law. Kim Yong Hyun resigned Thursday, and prosecutors imposed an overseas travel ban on him.NEW YORK (AP) — It’s that time of year: Spotify has released its annual Wrapped, personalized recaps of users’ listening habits and year in audio. Spotify has been giving its listeners breakdowns of their data since 2016. And each year, it’s become a bigger production — and internet sensation. Spotify said was the “biggest ever created,” in terms of audience reach and the kind of data it provided. So, what does 2024 have in store? Here’s a look at what to know. What exactly is Spotify Wrapped? It’s the streaming service’s annual overview of individual listening trends, as well as trends around the world. Users learn their top artists, songs, genres, albums and podcasts, all wrapped into one interactive presentation. The campaign has become a social media sensation, as people share and compare their Wrapped data with their friends and followers online. Wrapped provides users with all kinds of breakdowns and facts, including whether they’re among an artist’s top listeners, as well as a personalized playlist of their top 100 songs of that year to save, share and listen to whenever they’re feeling nostalgic. Spotify also creates a series of playlists that reflect national and global listening trends, featuring the top streamed artists and songs. In 2023, , unseating Bad Bunny who had held the title for three years in a row. She followed by The Weeknd, Bad Bunny, Drake and Billie Eilish. Where can I find my Spotify Wrapped? You should make sure your Spotify app is in order to get the full Wrapped experience. Wrapped is available to users with and without Premium subscriptions. Starting Wednesday, Spotify will prompt users to view their interactive data roundup on their smartphone or desktop app. You can also visit to find a QR code for that takes you straight to your data presentation. What else can I learn with my Spotify data? There are a handful of third-party sites that you can connect your Spotify account to that will analyze your Wrapped data. is an AI bot that judges your music taste. gives you your top songs on a sharable graphic that looks like, yes, a receipt. gives you your own personal music festival-style lineup based on your top artists. assesses how similar your music taste is to NPR Music’s. What if I don’t have Spotify? Other major streaming platforms such as Apple Music and YouTube Music have developed their own versions of Wrapped in recent years. not only gives its subscribers a year-end digest of their listening habits but monthly summaries as well — a feature that helps differentiate itself from the one-time Spotify recap. It was released on Dec. 3. YouTube Music, meanwhile, has a similar end-of-the-year release for its listeners, as well as periodic seasonal releases throughout the year. It released its annual Recap for users last month.
Giants release quarterback Daniel Jones just days after benching him EAST RUTHERFORD, N.J. (AP) — The Daniel Jones era in New York is over. The Giants quarterback was granted his release by the team just days after the franchise said it was benching him in favor of third-stringer Tommy DeVito. New York president John Mara said Jones approached the team about releasing him and the club obliged. Mara added he was “disappointed” at the quick dissolution of a once-promising relationship between Jones and the team. Giants coach Brian Daboll benched Jones in favor of DeVito following a loss to the Panthers in Germany that dropped New York's record to 2-8. Conor McGregor must pay $250K to woman who says he raped her, civil jury rules LONDON (AP) — A civil jury in Ireland has awarded more than $250,000 to a woman who says she was raped by mixed martial arts fighter Conor McGregor in a Dublin hotel penthouse after a night of heavy partying. The jury on Friday awarded Nikita Hand in her lawsuit that claimed McGregor “brutally raped and battered” her in 2018. The lawsuit says the assault left her heavily bruised and suffering from post-traumatic stress disorder. McGregor testified that he never forced her to do anything and that Hand fabricated her allegations after the two had consensual sex. McGregor says he will appeal the verdict. Week 16 game between Denver Broncos and Los Angeles Chargers flexed to Thursday night spot The Los Angeles Chargers have played their way into another prime time appearance. Justin Herbert and company have had their Dec. 22 game against the Denver Broncos flexed to Thursday night, Dec. 19. Friday’s announcement makes this the first time a game has been flexed to the Thursday night spot. The league amended its policy last season where Thursday night games in Weeks 13 through 17 could be flexed with at least 28 days notice prior to the game. The matchup of AFC West division rivals bumps the game between the Cleveland Browns and Cincinnati Bengals to Sunday afternoon. NBA memo to players urges increased vigilance regarding home security following break-ins MIAMI (AP) — The NBA is urging its players to take additional precautions to secure their homes following reports of recent high-profile burglaries of dwellings owned by Milwaukee Bucks forward Bobby Portis and Kansas City Chiefs teammates Patrick Mahomes and Travis Kelce. In a memo sent to team officials, a copy of which was obtained by The Associated Press, the NBA revealed that the FBI has connected some burglaries to “transnational South American Theft Groups” that are “reportedly well-organized, sophisticated rings that incorporate advanced techniques and technologies, including pre-surveillance, drones, and signal jamming devices.” Brock Purdy will miss Sunday's game for the 49ers with a shoulder injury SANTA CLARA, Calif. (AP) — San Francisco 49ers quarterback Brock Purdy will miss Sunday’s game against the Green Bay Packers with a sore throwing shoulder. Purdy injured his right shoulder in last Sunday’s loss to the Seattle Seahawks. Purdy underwent an MRI that showed no structural damage but the shoulder didn’t improve during the week and Purdy was ruled out for the game. Coach Kyle Shanahan said star defensive end Nick Bosa also will miss the game with injuries to his left hip and oblique. Left tackle Trent Williams is questionable with an ankle injury and will be a game-time decision. Red Bull brings wrong rear wing to Las Vegas in mistake that could stall Verstappen's title chances LAS VEGAS (AP) — Max Verstappen is suddenly in jeopardy of being denied a fourth consecutive Formula 1 title Saturday night. Red Bull apparently brought the wrong rear wing to Las Vegas and GPS data showed its two cars to be significantly slower on the straights than both McLaren and Mercedes, which led both practice sessions. Red Bull says it doesn’t have a replacement rear wing in Las Vegas to fix the issue and little chance of getting two flown in from England ahead of the race. Lawyer says ex-Temple basketball standout Hysier Miller met with NCAA for hours amid gambling probe PHILADELPHIA (AP) — A lawyer for former Temple basketball standout Hysier Miller says the 22-year-old sat for a long interview with the NCAA amid an investigation into unusual gambling activity. But neither the lawyer nor federal law enforcement officials on Friday would confirm reports that a federal probe is now under way. Lawyer Jason Bologna says Miller cooperated because he hopes to play again. Miller was released last month after transferring to Virginia Tech. Temple President John Fry says the Philadelphia school has not been asked for any information from federal law enforcement officials. Caitlin Clark to join Cincinnati bid for 16th National Women's Soccer League team WNBA star Caitlin Clark has joined Cincinnati’s bid for an expansion National Women’s Soccer League team. Major League Soccer franchise FC Cincinnati is heading the group vying to bring a women’s pro team to the city. The club issued a statement confirming Clark had joined the bid group. NWSL Commissioner Jessica Berman has said the league plans to announce the league’s 16th team by the end of the year. The league's 15th team will begin play in 2026 in Boston. Alyssa Nakken, first full-time female coach in MLB history, leaving Giants to join Guardians CLEVELAND (AP) — Alyssa Nakken, the first woman to coach in an MLB game, is leaving the San Francisco Giants to join the Cleveland Guardians. Nakken made history in 2022 when she took over as first-base coach following an ejection. A former college softball star at Sacramento State, Nakken joined the Giants in 2014 and was promoted to a spot on manager Gabe Kapler’s staff in 2020, becoming the majors’ first full-time female coach. Nakken has been hired as an assistant director within player development for the Guardians, who won the AL Central last season under first-year manager Stephen Vogt. Nakken, 34, will work with former Giants coaches Craig Albernaz and Kai Correa. Aaron Judge won't be bothered if Juan Soto gets bigger contract from Yankees than his $360M deal NEW YORK (AP) — Aaron Judge won’t be bothered if Juan Soto gets a bigger deal from the New York Yankees than the captain’s $360 million, nine-year contract. Speaking a day after he was a unanimous winner of his second MVP, Judge says “It ain’t my money” and adds "that’s never been something on my mind about who gets paid the most.” Judge led the major leagues with 58 homers, 144 RBIs and 133 walks while hitting .322. Soto batted .288 with 41 homers, 109 RBIs and 129 walks in his first season with the Yankees, then became a free agent at age 26.Join our daily and weekly newsletters for the latest updates and exclusive content on industry-leading AI coverage. Learn More In a world where efficiency is king and disruption creates billion-dollar markets overnight, it’s inevitable that businesses are eyeing generative AI as a powerful ally. From OpenAI’s ChatGPT generating human-like text, to DALL-E producing art when prompted, we’ve seen glimpses of a future where machines create alongside us — or even lead the charge. Why not extend this into research and development (R&D)? After all, AI could turbocharge idea generation, iterate faster than human researchers and potentially discover the “next big thing” with breathtaking ease, right? Hold on. This all sounds great in theory, but let’s get real: Betting on gen AI to take over your R&D will likely backfire in significant, maybe even catastrophic, ways. Whether you’re an early-stage startup chasing growth or an established player defending your turf, outsourcing generative tasks in your innovation pipeline is a dangerous game. In the rush to embrace new technologies, there’s a looming risk of losing the very essence of what makes truly breakthrough innovations — and, worse yet, sending your entire industry into a death spiral of homogenized, uninspired products. Let me break down why over-reliance on gen AI in R&D could be innovation’s Achilles’ heel. 1. The unoriginal genius of AI: Prediction ≠ imagination Gen AI is essentially a supercharged prediction machine. It creates by predicting what words, images, designs or code snippets fit best based on a vast history of precedents. As sleek and sophisticated as this may seem, let’s be clear: AI is only as good as its dataset. It’s not genuinely creative in the human sense of the word; it doesn’t “think” in radical, disruptive ways. It’s backward-looking — always relying on what’s already been created. In R&D, this becomes a fundamental flaw, not a feature. To truly break new ground, you need more than just incremental improvements extrapolated from historical data. Great innovations often arise from leaps, pivots, and re-imaginings, not from a slight variation on an existing theme. Consider how companies like Apple with the iPhone or Tesla in the electric vehicle space didn’t just improve on existing products — they flipped paradigms on their heads. Gen AI might iterate design sketches of the next smartphone, but it won’t conceptually liberate us from the smartphone itself. The bold, world-changing moments — the ones that redefine markets, behaviors, even industries — come from human imagination, not from probabilities calculated by an algorithm. When AI is driving your R&D, you end up with better iterations of existing ideas, not the next category-defining breakthrough. 2. Gen AI is a homogenizing force by nature One of the biggest dangers in letting AI take the reins of your product ideation process is that AI processes content — be it designs, solutions or technical configurations — in ways that lead to convergence rather than divergence. Given the overlapping bases of training data, AI-driven R&D will result in homogenized products across the market. Yes, different flavors of the same concept, but still the same concept. Imagine this: Four of your competitors implement gen AI systems to design their phones’ user interfaces (UIs). Each system is trained on more or less the same corpus of information — data scraped from the web about consumer preferences, existing designs, bestseller products and so on. What do all those AI systems produce? Variations of a similar result. What you’ll see develop over time is a disturbing visual and conceptual cohesion where rival products start mirroring one another. Sure, the icons might be slightly different, or the product features will differ at the margins, but substance, identity and uniqueness? Pretty soon, they evaporate. We’ve already seen early signs of this phenomenon in AI-generated art. In platforms like ArtStation, many artists have raised concerns regarding the influx of AI-produced content that, instead of showing unique human creativity, feels like recycled aesthetics remixing popular cultural references, broad visual tropes and styles. This is not the cutting-edge innovation you want powering your R&D engine. If every company runs gen AI as its de facto innovation strategy, then your industry won’t get five or ten disruptive new products each year — it’ll get five or ten dressed-up clones. 3. The magic of human mischief: How accidents and ambiguity propel innovation We’ve all read the history books: Penicillin was discovered by accident after Alexander Fleming left some bacteria cultures uncovered. The microwave oven was born when engineer Percy Spencer accidentally melted a chocolate bar by standing too close to a radar device. Oh, and the Post-it note? Another happy accident — a failed attempt at creating a super-strong adhesive. In fact, failure and accidental discoveries are intrinsic components of R&D. Human researchers, uniquely attuned to the value hidden in failure, are often able to see the unexpected as opportunity. Serendipity, intuition, gut feeling — these are as pivotal to successful innovation as any carefully laid-out roadmap. But here’s the crux of the problem with gen AI : It has no concept of ambiguity, let alone the flexibility to interpret failure as an asset. The AI’s programming teaches it to avoid mistakes, optimize for accuracy and resolve data ambiguities. That’s great if you’re streamlining logistics or increasing factory throughput, but it’s terrible for breakthrough exploration. By eliminating the possibility of productive ambiguity — interpreting accidents, pushing against flawed designs — AI flattens potential pathways toward innovation. Humans embrace complexity and know how to let things breathe when an unexpected output presents itself. AI, meanwhile, will double down on certainty, mainstreaming the middle-of-road ideas and sidelining anything that looks irregular or untested. 4. AI lacks empathy and vision — two intangibles that make products revolutionary Here’s the thing: Innovation is not just a product of logic; it’s a product of empathy, intuition, desire, and vision. Humans innovate because they care, not just about logical efficiency or bottom lines, but about responding to nuanced human needs and emotions. We dream of making things faster, safer, more delightful, because at a fundamental level, we understand the human experience. Think about the genius behind the first iPod or the minimalist interface design of Google Search. It wasn’t purely technical merit that made these game-changers successful — it was the empathy to understand user frustration with complex MP3 players or cluttered search engines. Gen AI cannot replicate this. It doesn’t know what it feels like to wrestle with a buggy app, to marvel at a sleek design, or to experience frustration from an unmet need. When AI “innovates,” it does so without emotional context. This lack of vision reduces its ability to craft points of view that resonate with actual human beings. Even worse, without empathy, AI may generate products that are technically impressive but feel soulless, sterile and transactional — devoid of humanity. In R&D, that’s an innovation killer. 5. Too much dependence on AI risks de-skilling human talent Here’s a final, chilling thought for our shiny AI-future fanatics. What happens when you let AI do too much ? In any field where automation erodes human engagement, skills degrade over time. Just look at industries where early automation was introduced: Employees lose touch with the “why” of things because they aren’t flexing their problem-solving muscles regularly. In an R&D-heavy environment, this creates a genuine threat to the human capital that shapes long-term innovation culture. If research teams become mere overseers to AI-generated work, they may lose the capability to challenge, out-think or transcend the AI’s output. The less you practice innovation, the less you become capable of innovation on your own. By the time you realize you’ve overshot the balance, it may be too late. This erosion of human skill is dangerous when markets shift dramatically, and no amount of AI can lead you through the fog of uncertainty. Disruptive times require humans to break outside conventional frames — something AI will never be good at. The way forward: AI as a supplement, not a substitute To be clear, I’m not saying gen AI has no place in R&D — it absolutely does. As a complementary tool, AI can empower researchers and designers to test hypotheses quickly, iterate through creative ideas, and refine details faster than ever before. Used properly, it can enhance productivity without squashing creativity. The trick is this: We must ensure that AI acts as a supplement, not a substitute, to human creativity. Human researchers need to stay at the center of the innovation process, using AI tools to enrich their efforts — but never abdicating control of creativity, vision or strategic direction to an algorithm. Gen AI has arrived, but so too has the continued need for that rare, powerful spark of human curiosity and audacity — the kind that can never be reduced to a machine-learning model. Let’s not lose sight of that. Ashish Pawar is a software engineer . DataDecisionMakers Welcome to the VentureBeat community! DataDecisionMakers is where experts, including the technical people doing data work, can share data-related insights and innovation. If you want to read about cutting-edge ideas and up-to-date information, best practices, and the future of data and data tech, join us at DataDecisionMakers. You might even consider contributing an article of your own! Read More From DataDecisionMakers
How to Watch the NBA Today, December 29
Skattebo and Arizona State to the playoff after 45-19 win over Iowa State in Big 12 title game ARLINGTON, Texas (AP) — Big 12 newcomer Arizona State will represent the conference in the 12-team College Football Playoff. Cam Skattebo ran for 170 yards and two scores while adding a touchdown catch the 12th-ranked Sun Devils beat No. 16 Iowa State 45-19 in the Big 12 championship game. The Sun Devils with 34-year-old head coach Kenny Dillingham are 11-2 after being the preseason pick to finish at the bottom of their new 16-team league. They have won six games in a row. Iowa State is 10-3, already the first 10-win season in the program's 133-year history. Boise State makes the College Football Playoff as Big 12's 1st-round bye chances dim INDIANAPOLIS (AP) — The first big win in college football’s postseason goes to Boise State. The have Broncos captured the Mountain West Conference title and earned their spot in the sport’s first 12-team playoff. As for the losers, there was UNLV, which fell 21-7 to Heisman hopeful Ashton Jeanty and the Broncos in the conference title game. But more than that, it was the Big 12, which saw one path to a first-round bye in those playoffs blocked off by Jeanty and Company. Lindsey Vonn competes in a pair of downhills, another step on her comeback trail at the age of 40 COPPER MOUNTAIN, Colo. (AP) — Lindsey Vonn finished in the middle of the pack in a pair of lower-level downhill events as she competed for the first time in nearly six years. The 40-year-old Vonn is on the comeback trail after stepping away from the sport because of injuries. Vonn wasn't concerned with times and places in the races so much as getting used to the speed again and gaining the necessary points to compete on the World Cup circuit. Vonn accomplished both, finishing 24th in the first downhill race of the day and 27th in the second. She posted on social media after the FIS races she had enough points to enter World Cup events. Man City drops more points after draw with Crystal Palace and Man United loses again Manchester City’s Premier League title defense has taken another blow after a 2-2 draw with Crystal Palace. Four-time defending champion City ended a seven-game winless run on Wednesday by beating Nottingham Forest. But City has dropped more points on Saturday after the draw at Selhurst Park. It could have been worse for City after Palace led twice. Pep Guardiola’s team is fourth in the standings and eight points behind leader Liverpool. Liverpool has a game in hand after its derby with Everton was postponed due to a storm. Amber Glenn becomes first US woman in 14 years to win figure skating Grand Prix Final GRENOBLE, France (AP) — Amber Glenn has become the first American to win the women’s Grand Prix Final competition since Alissa Czisny 14 years ago. Glenn landed a triple axel on her way to a total score of 212.07 points to beat Japan's Mone Chiba and triple world champion Kaori Sakamoto. That continues a stunning breakout season at the age of 25 for Glenn. The U.S. could win two more titles later Saturday. Ilia Malinin leads the men’s event ahead of the free skate and Madison Chock and Evan Bates lead the ice dance. Norris takes pole for season-ending Abu Dhabi GP and Hamilton 18th in Mercedes farewell ABU DHABI, United Arab Emirates (AP) — Lando Norris took pole position for the last Formula 1 race of the season alongside teammate Oscar Piastri to put McLaren on the verge of a first constructors’ title in 26 years. Norris’ last lap put him .209 of a second faster than Piastri, with Ferrari’s Carlos Sainz Jr. .020 further back. Seven-time F1 champion Hamilton qualified 18th for his last race with Mercedes after a bizarre incident wrecked his final qualifying lap. A plastic pole marking the inside of a corner was knocked loose by Kevin Magnussen’s Haas and Hamilton drove over it. Big 12's Yormark brings up hard choices for fans before sparsely attended title game ARLINGTON, Texas (AP) — College football fans are facing some hard choices in the expanded playoff system with some teams set to play away from home multiple times. Big 12 Commissioner Brett Yormark raised that point before the sparsely attended title game between No. 12 Arizona State and 16th-ranked Iowa State. There were thousands of empty seats at the home of the Dallas Cowboys. Yormark says he remains committed to having a Big 12 title game. Besides the issues of fans, there have been suggestions that some leagues might be better off without title games as it relates to playoff hopes. Everton vs. Liverpool postponed because of Storm Darragh. Other Premier League games remain on LIVERPOOL, England (AP) — The Merseyside derby between Everton and Liverpool has been postponed because of Storm Darragh's dangerous winds and heavy rain on the west coast. The Met office says parts of Wales have experienced wind gusts of over 90 mph. The four other Premier League games Saturday remained on as planned. Manchester United will host Nottingham Forest at 5:30 p.m. local time at Old Trafford. The remaining games start at 3 p.m. local time. Aston Villa hosts Southampton and urged fans to use extra time to get to Villa Park in Birmingham. In London, Brentford will host Newcastle, and Crystal Palace will host Manchester City. Ashton Jeanty lets his play do the talking for CFP-bound Boise State BOISE, Idaho (AP) — After Ashton Jeanty streaked through the middle of UNLV’s defense on his way to a 75-yard touchdown run Friday night in the Mountain West Conference title game, he didn’t strike the Heisman pose. He didn’t even lobby for it after the game, instead letting his play do the talking in No. 10 Boise State's 21-7 victory over No. 19 UNLV 21-7. Jeanty added another 209 yards — his sixth game over 200 yards this season — to push his total to 2,497 — just 132 yards short of passing Barry Sanders’ FBS season rushing record. The Broncos earned a spot in the College Football Playoff with the victory. No. 24 Army wins AAC championship in first attempt as Daily runs for 4 TDs in 35-14 win over Tulane WEST POINT, N.Y. (AP) — Bryson Daily rushed for four touchdowns to tie the American Athletic Conference championship game record, and No. 24 Army completed a perfect first season in the league by beating Tulane 35-14. Kanye Udoh rushed for 158 yards, including a 72-yarder to set up a Daily TD, and a score. Daily added 126 yards on the ground for the Black Knights, who overwhelmed AAC opponents with their bruising, clock-eating rushing attack during their first around the league, then ran it to perfection in the championship game. Army moved to 11-1. Daily had runs of 5, 3, 4 and 7 yards.NEW YORK — Nebraska football writer Luke Mullin offers his extra points from the Husker football team's 20-15 bowl game win over Boston College on Saturday. Play of the game: Rahmir Johnson's fourth-down conversion late in the fourth quarter. On a play where Nebraska needed to gain 1 yard to ice the game, Johnson came up with 11 instead and gained a first down that the Huskers simply needed to have. Had he been stopped short, Boston College could've gotten a chance to come all the way back for a win, but Johnson ensured that didn't happen. Turning point: Boston College's missed field goal in the first quarter. Having intercepted a Dylan Raiola pass, the Eagles drove into Nebraska territory and had a chance to take a 3-0 lead. When the drive stalled out and BC's long field goal try missed, momentum was back on NU's side, where it remained for much of the game. Quotable: "I don't think you should say 6-7 (record), that's such a miserable thought right now. Let's be positive, guys, we just won a bowl game!" Nebraska head coach Matt Rhule on what it meant to end the season with a win. Game ball: Rahmir Johnson. The MVP of the bowl game certainly deserves a game ball, and Johnson earned it as the hometown hero playing in front of family and friends. The sixth-year senior played one of his best games as a Husker in his final game with the team. Game ball: The entire Nebraska defense. The final score shows that it was a close game, and it's only that way because of Nebraska's ability to stop Boston College inside its own territory. A below-average game from the Husker defense could've led to a BC win instead, but Nebraska played at a high level and won the game because of it. Hat tip: To Dylan Raiola, who made big passes and gained key yardage with his legs when the situation required it. An early interception didn't do much to detract from Raiola's performance as the true freshman led Nebraska to a win. Questionable: There wasn't much to complain about, but Nebraska's decision to attempt a fake field goal might just warrant it. Given that the Huskers had already converted a fake punt, Boston College was bound to be alert for the chance of a fake and indeed it was. There was no issue with going for the try, but Nebraska would've been better served by keeping its offense on the field rather than trying some trickery once again. Tone-setter: Jahmal Banks' one-handed catch. While it didn't lead to any points, Banks' grab showed that Nebraska was going to go after the one-on-one matchup that BC afforded it. The Huskers made great use of those situations to move the ball all game long. 10: Different Huskers who caught a pass on Saturday, including defensive back Isaac Gifford. 7: Consecutive Boston College drives which ended without points to begin the game. 2-for-2: Punter Brian Buschini's passing statistics this season, having thrown for 38 yards on his two tries. 7: Tackles for a loss recorded by the Nebraska defense, three of which being quarterback sacks. 3,290: Days since Nebraska's last bowl game win during the 2015 season. Get local news delivered to your inbox!
Seven major astrological shifts happening in 2025 that will bring huge 'shakeups'AP Business SummaryBrief at 1:12 p.m. EST
Degrees were handed out to 391 graduates and undergraduates at the University of Nebraska at Kearney Friday at the UNK Health and Sport Center. Interim Chancellor Charlie Bicak conferred degrees. University of Nebraska System President Dr. Jeffrey P. Gold delivered the keynote address. Winter commencement exercises brought together graduates, their friends and families, UNK staff and more. The student speaker was Emily Conrad of Gretna, who graduated summa cum laude with a bachelor’s degree in business administration with a management emphasis. A Gretna native, Conrad was an active participant in the College of Business and Technology Living-Learning Community, serving as a mentor and leading community service events and business tours. The student speaker was Emily Conrad of Gretna, who graduated summa cum laude with a bachelor’s degree in business administration with a management emphasis. Also addressing the graduates was NU Board of Regents Vice Chair Paul Kenney. The national anthem was performed by Class of 2024 members Abbygail Marshall of North Platte and Megumi Sakamoto of Toyama, Japan, who both graduated magna cum laude. Interview of Carsyn McBride, a two-time tournament champion wrestler this season for Kearney High. Get our local education coverage delivered directly to your inbox.On the 16th day, Bryson DeChambeau finally got his hole-in-one. The LIV golfer and started a challenge earlier this month of attempting to make a hole-in-one while hitting golf balls over his house and onto a backyard putting green. The number of shots DeChambeau would attempt would depend on what day of the challenge he was on — so one shot on the first day, two on the second day, and so on. On Wednesday, DeChambeau's achieved his goal with a wedge on his 14th attempt of the day and his 134th overall shot. What a journey — Bryson DeChambeau (@brysondech) “I can’t believe I made that, finally! Are you kidding me?!” DeChambeau said before falling to the ground in disbelief. “That’s enough.” There were close calls along the way, . But successfully sinking a hole-in-one early in this would it? As for holes-in-one during his career, DeChambeau has only made one — during the final round of the on the 16th hole.
At a glance Expert's Rating Pros Generous selection of ports Long battery life Good performance Cons Bad trackpad The Intel version is faster Arm PCs still have compatibility drawbacks Dim display Our Verdict Price When Reviewed This value will show the geolocated pricing text for product undefined Best Pricing Today The Acer Swift 14 AI looks like an unimposing laptop that could easily be mistaken for any number of machines in Acer's lineup. It has a secret inside, though. The Swift 14 AI is Acer's first Arm-based notebook, running on Qualcomm's Snapdragon X Elite processor. Laptops have changed a lot in the last few years as Arm-based chips have finally gotten powerful enough to run Windows. The Acer Swift 14 AI might not be the best representative of that change, though. The Acer Swift 14 AI is slim and efficient, running for ages before it needs to recharge. It also has a pretty generous selection of ports for a thin-and-light laptop. However, the trackpad is below average, and there's entirely too much bloatware. There are also issues that aren't Acer's fault—emulated apps don't always work right and some hardware won't play nice with Arm PCs. For the right price, the Acer Swift 14 AI can be a fine entrée to the world of Copilot+ PCs, but that price is not the MSRP. Acer Swift 14 AI: Specs and features You won't have to make any difficult choices when purchasing the Acer Swift 14 AI. There are only two variants of the machine, one with a touchscreen and the other without. Both display options are the same 2560×1600 IPS. The touch version (which I have been testing) is $1,099.99, and the non-touch version is $1,049.99. The specifications are identical, so there's no reason not to get the touch version for an extra $50. Inside, the Acer Swift 14 AI sports a Qualcomm Snapdragon X Elite (X1E-78-100), a 12-core Arm processor that we've seen in laptops like Dell XPS 13 (9345). The capable Oryon CPU cores are backed up by an integrated Adreno... Author , Ryan Whitwam , .Wp-Block-Co-Authors-Plus-Coauthors.Is-Layout-Flow , Class , Wp-Block-Co-Authors-Plus , Display Inline , .Wp-Block-Co-Authors-Plus-Avatar , Where Img , Height Auto Max-Width , Vertical-Align Bottom .Wp-Block-Co-Authors-Plus-Coauthors.Is-Layout-Flow .Wp-Block-Co-Authors-Plus-AvatarChina demonstrates composure and confidence, injects stability into a turbulent world Reports Global Times
Love Island's Millie Court recounted a frightening encounter while on holiday in Australia with her boyfriend Liam Reardon. The 28 year old reality TV star revealed she was stung by a jellyfish, also known as a bluebottle, while swimming in the sea despite warning signs on the beach. Millie posted footage of the jellyfish and her subsequent rash on social media, sharing: "Goes into sea to get taken out by a huge wave, come up above water to find a blue jellyfish wrapped round my neck, in my hair, tentacles all round my stomach. I've never screamed so loud." She took responsibility for the incident, stating: "It's my own fault." Following the lifeguards' advice, Millie took a hot shower and applied ice to numb the pain, noting the rash would be itchy for about an hour. Read more Janette Manrara shares plans to expand family with Aljaz Skorjanec after 'tough loss' The influencer preemptively addressed potential criticism, insisting: "And before you say 'why on earth would you go in the sea then', there's so many people in there that were also unfazed and the lifeguards don't tell you to not go in so we thought, 'f*** it, it'll be fine'." Millie has been enjoying the festive season in Sydney with Liam and her friend Chloe Burrows, a fellow Love Island contestant, reports the Mirror . Before the mishap, Millie kept her followers envious with updates from their opulent beachside Christmas celebrations in Sydney. On social media, she expressed, "MERRY CHRISTMAS all the way from Sydney, Australia. It's now actually Boxing Day for us but we had the BEST time spending the day on the beach with all our friends. Wishing you all a merry Christmas and a happy new year." The loved-up pair who triumphed in the 2021 series of the ITV2 show moved into a swanky £1 million mansion in Essex. Fans were taken aback when the couple split in 2022, but they soon rekindled their romance. Despite living apart, with Millie in Essex and Liam in Wales, the distance has only strengthened their bond. While Millie eagerly anticipates a proposal from Liam, she hasn't been shy about hinting at her perfect engagement scenario and dream ring style, as per her recent chat with MailOnline: "Not that it means he'll do it any time soon but I thought better he knows now so when he does decide to, in the future, he knows what ring I like. He also knows what I would like proposal-wise as well, so where it would be and stuff," she disclosed.Wild first season in expanded Big 12 comes down to final weekendKash Patel: The die-hard loyalistIn college hoops play on Thursday, the Butler Bulldogs versus the Northwestern Wildcats is among the 10 games that made our list of best bets against the spread. Watch men’s college basketball, other live sports and more on Fubo. What is Fubo? Fubo is a streaming service that gives you access to your favorite live sports and shows on demand. Use our link to sign up for a free trial. Not all offers available in all states, please visit BetMGM for the latest promotions for your area. Must be 21+ to gamble, please wager responsibly. If you or someone you know has a gambling problem, contact 1-800-GAMBLER .
Why Is It OK for Everyone but Israelis to Defend Themselves? | Opinion
Dominated by Ohio State for years, Indiana has a chance for the big payback
As her students finished their online exam, Arlet Lara got up to make a cafe con leche. Her 16-year-old son found her on the kitchen floor. First, he called Dad in a panic. Then 911. “I had a stroke, and my life made a 180-degree turn,” Lara said, recalling the medical scare she experienced in May 2020 in the early months of the COVID-19 pandemic. “The stroke affected my left side of the body.” Lara, an avid runner and gym-goer couldn’t even walk. “It was hard,” said the 50-year-old mom from North Miami and former high school math teacher. After years of rehabilitation therapy and a foot surgery, Lara can walk again. But she still struggles with moving. This summer, she became the first patient in South Florida to get an implant of a new and only FDA-approved-nerve stimulation device designed to help ischemic stroke survivors regain movement in their arms and hands. People are also reading... Every year, thousands in the United States have a stroke, with one occurring every 40 seconds, according to the U.S. Centers for Disease Control and Prevention. The majority of strokes are ischemic, often caused by blood clots that obstruct blood flow to the brain. For survivors, most of whom are left with some level of disability, the Vivistim Paired VNS System — the device implanted in Lara’s chest — could be a game changer in recovery, said Dr. Robert Starke, a neurosurgeon and interventional neuroradiologist. He also serves as co-director of endovascular neurosurgery at Jackson Memorial Hospital, where Lara underwent the procedure. The Vivistim Paired VNS System is a small pacemaker-like device implanted in the upper chest and neck area. Patients can go home the same day. The U.S. Food and Drug Administration approved the stroke rehabilitation system in 2021 to be used alongside post-ischemic stroke rehabilitation therapy to treat moderate to severe mobility issues in hands and arms. Lara’s occupational therapist can activate the device during rehabilitation sessions to electrically stimulate the vagus nerve, which runs from the brain down to the abdomen and regulates various parts of the body’s nervous system. The electrical stimulation rewires the brain to improve a stroke survivor’s ability to move their arms and hands. Lara also has a magnet she can use to activate the device when she wants to practice at home. Her therapy consists of repetitive tasks, including coloring, pinching cubes and grabbing and releasing cylindrical shapes. After several weeks of rehabilitation therapy with the device, Lara has seen improvement. “Little by little, I’m noticing that my hand is getting stronger,” Lara said in September. “I am already able to brush my teeth with the left hand.” Since then, Lara has finished the initial six-week Vivistim therapy program and is continuing to use the device in her rehabilitation therapy. She continues to improve and can now eat better with her left hand and can brush her hair with less difficulty, according to her occupational therapist, Neil Batungbakal. Starke sees the device as an opportunity to help bring survivors one step closer to regaining full mobility. Strokes are a leading cause of disability worldwide. While most stroke survivors usually can recover some function through treatment and rehabilitation, they tend to hit a “major plateau” after the first six months of recovery, he said. Vivistim, when paired with rehabilitation therapy, could change that. Jackson Health said results of a clinical trial published in the peer-reviewed medical journal The Lancet in 2021 showed that the device, “when paired with high-repetition, task-specific occupational or physical therapy, helps generate two to three times more hand and arm function for stroke survivors than rehabilitation therapy alone.” The device has even shown to benefit patients 20 years after their original stroke, according to Starke. “So now a lot of these patients that had strokes 10 to 15 years ago that thought that they would never be able to use their arm in any sort of real functional way are now able to have a real meaningful function, which is pretty tremendous,” Starke said. Vivistim’s vagus-nerve stimulation technology was developed by researchers at the University of Texas at Dallas’ Texas Biomedical Device Center and is being sold commercially by Austin-based MicroTransponder, a company started by university graduates. Similar devices are used to treat epilepsy and depression. For Lara, the device is a new tool to help her recovery journey. “Everything becomes a challenge, so we are working with small things every day because I want to get back as many functions as possible,” Lara said. Patients interested in Vivistim should speak with their doctor to check their eligibility. The FDA said patients should make sure to discuss any prior medical history. “Adverse events included but were not limited to dysphonia (difficulty speaking), bruising, falling, general hoarseness, general pain, hoarseness after surgery, low mood, muscle pain, fracture, headache, rash, dizziness, throat irritation, urinary tract infection and fatigue,” the FDA said. MicroTransponder says the device is “covered by Medicare, Medicaid and private insurance with prior authorization on a case-by-case basis.” Get local news delivered to your inbox!SAINT PAUL, Minn. (AP) — Mariah Keopple and Alexandra Labelle scored their first goals of the season and the Montreal Victoire edged the Minnesota Frost 3-2 on Saturday. Marie-Philip Poulin's goal almost six minutes into the second period was the difference as she converted a 2-on-1 from Laura Stacey and Jennifer Gardiner and Montreal (2-2-0-1), which went 0 for 3 on the power play, won its third straight while handing Minnesota (3-1-1-1) its first regulation loss of the season. Despite having the better control of the action from the start Montreal fell behind 1-0 near the middle of the first period when Claire Thompson and Taylor Heise set up Britta Curl-Salemme for her third goal of the season. But in the last five minutes of the period Keopple scored on a pass from Claire Dalton, and Labelle banged in a rebound of her initial shot. Minnesota pulled into a tie at just 3:17 into the second period when Brooke McQuigge picked up her first goal during a scramble in front of the Montreal goal. Barely 2 1/2 minutes later the Victoire were back on top on Poulin's second goal of the season and Ann-Renee Desbiens, who made 22 saves, made that stand up. Maddie Rooney made 22 saves for Minnesota, which went 0-1 on the power play. Boston plays at Montreal on Monday. The Frost are home against Boston on Thursday. ___ AP women’s hockey: https://apnews.com/hub/womens-hockey The Associated Press
'Open your doors': Notre Dame re-opens after five-year refitFor all the talk of diversity, equity, and inclusion (DEI) from the Democratic Party , the 2024 election results demonstrate that its voter base has ironically become less diverse. Exit polls show that Democrats lost ground across a broad range of voter groups—Hispanics, Asians, Blacks, and both the working and middle class. The only demographic where they made notable gains at the presidential level was among college-educated white voters . So, what went wrong? For years, DEI experts told us that viewing racial issues through the lens of colorblind equality overlooked the unique struggles of oppressed groups. They claimed that without addressing racial disparities head-on, often by discriminating against majority groups, real progress wouldn't be made. It turns out they were wrong. Because they bought into the DEI agenda, Democrats were too busy trying to look diverse to actually listen to the concerns of diverse groups of people. Prioritizing "representation" of minorities meant compromising on the quality of their candidate pool. Prior to picking Kamala Harris as his running mate, President Joe Biden specifically said he'd prefer to pick a candidate "who was of color and/or a different gender." The media praised Harris' selection as a " historic " choice of the first Black and Asian woman to be nominated for vice president, despite her being one of the least popular candidates among Democrats in 2020. And in 2024, Democrats paid a hefty price for choosing a candidate based on identity rather than merit. The Democrats' sacrifice of merit for identity only alienated minority voters in their base. Minority voters have grown tired of the paternalistic attitude DEI-obsessed progressives have fostered. Academics infamously tried to impose the gender-neutral term "Latinx" onto Hispanics. Coined around 2004 , the term gained prominence throughout the last decade, with Merriam Webster adding the word to its dictionary in 2018 . But Hispanics consistently rejected being referred to as "Latinx." Academics and progressives ignored their complaints. And now a recent study shows that Hispanics are less likely to vote for candidates who use the term. Democrats' focus on identity politics also alienated Asian-American voters. Shortly after the Supreme Court ruled against race-based discrimination in college admissions, many Democrats voiced their disdain for the decision. Senate Majority Leader Chuck Schumer (D-N.Y.) called the decision "a giant roadblock in our country's march toward racial justice." What they effectively communicated to Asian Americans—who were, as the Court recognized, disproportionately penalized by affirmative action —is that Democrats and elite institutions would not stand up for them against racial discrimination. Moreover, in 2020, Asian Americans were at the forefront of the fight to defeat California's Prop 16 , which would have restored affirmative action in the state's public universities. Although Black voters remain a key voting bloc for Democrats, the Trump campaign still made surprising inroads with the group—especially among Black men. Perhaps the infantilizing rhetoric Democrats regularly use towards Black people can provide a clue as to why those voters have started to move away from the party. New York governor Kathy Hochul's gaffe—implying Black children in the Bronx didn't know what computers were—perfectly exhibits how dismissively Democrats view the Black community. Just weeks before the election, former president Barack Obama publicly shamed Black men who supported Trump over Harris. If Democrats continue down this path, they risk pushing Black voters into the arms of the Republican Party , just like they did with Hispanics and Asians. Ironically, all the emphasis on DEI seemed to resonate most with college-educated white voters, who remained a Democratic stronghold in 2024. In other words, DEI was never truly about helping minorities; it was about allowing wealthy white elites to feel better about themselves. As much as the media, universities, and some Democratic leaders want to attribute the results of the 2024 election to racism and sexism , the truth is that Democrats were out of touch. Voters, including minority voters, were worried about inflation and border security, and Republicans were addressing those issues. Ignoring those concerns and doubling down on DEI will only continue to make the Democratic coalition less diverse. Neetu Arnold is a Paulson Policy Analyst at the Manhattan Institute and a Young Voices contributor. Follow her on X @neetu_arnold The views expressed in this article are the writer's own.
- Previous: bmy88 net register
- Next: bmy888 net l
